Immunome, Inc. (IMNM)

NASDAQ: IMNM · Real-Time Price · USD
8.79
+0.25 (2.93%)
At close: Apr 30, 2025, 4:00 PM
8.88
+0.09 (1.02%)
Pre-market: May 1, 2025, 7:10 AM EDT
2.93%
Market Cap 764.30M
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
Shares Out 86.95M
EPS (ttm) -5.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,120,302
Open 8.33
Previous Close 8.54
Day's Range 8.31 - 8.94
52-Week Range 5.15 - 19.07
Beta 2.06
Analysts Strong Buy
Price Target 26.00 (+196.3%)
Earnings Date May 13, 2025

About IMNM

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-13... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 118
Stock Exchange NASDAQ
Ticker Symbol IMNM
Full Company Profile

Financial Performance

In 2024, Immunome's revenue was $9.04 million, a decrease of -35.50% compared to the previous year's $14.02 million. Losses were -$292.96 million, 174.3% more than in 2023.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $26.0, which is an increase of 196.30% from the latest price.

Price Target
$26.0
(196.30% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The comp...

14 days ago - Seeking Alpha

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...

26 days ago - Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...

27 days ago - Business Wire

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...

6 weeks ago - Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first...

7 weeks ago - Business Wire

Immunome to Present at Upcoming March Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...

2 months ago - Business Wire

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...

3 months ago - Business Wire

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Can Take The Fight To Competitors With Varegacestat

3 months ago - Seeking Alpha

Immunome Announces Pricing of Upsized Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...

3 months ago - Business Wire

Immunome Announces Proposed Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced i...

3 months ago - Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

3 months ago - Business Wire

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome'...

5 months ago - Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update.

6 months ago - Business Wire

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

6 months ago - Business Wire

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising p...

6 months ago - Business Wire

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...

6 months ago - Business Wire

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the ...

7 months ago - Business Wire

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...

8 months ago - Business Wire

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...

8 months ago - Business Wire

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced fina...

9 months ago - Business Wire

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today provided an update on re...

9 months ago - Business Wire

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $...

10 months ago - Seeking Alpha

Immunome Appoints Phil Tsai as Chief Technical Officer

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...

10 months ago - Business Wire

Immunome Announces Completion of Purchase of Assets from Atreca

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion...

1 year ago - Business Wire

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion ...

1 year ago - Business Wire